{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:50:44Z","timestamp":1780383044236,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.msard.2022.103772","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:13:11Z","timestamp":1648210391000},"page":"103772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series"],"prefix":"10.1016","volume":"61","author":[{"given":"Takashi","family":"Yamamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsusada","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Cherng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnosuke","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-Christian","family":"von B\u00fcdingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuichi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103772_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.608149","article-title":"Early treatment initiation with oral prednisolone for relapse prevention alleviates depression and fatigue in Aquaporin-4-positive neuromyelitis optica pectrum disorder","volume":"12","author":"Akaishi","year":"2021","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103772_bib0002","article-title":"AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders","volume":"7","author":"Asseyer","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2022.103772_bib0003","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: Patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.103772_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102538","article-title":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","volume":"46","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2022.103772_bib0005","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.msard.2022.103772_bib0006","unstructured":"European Medicines Agency, 2021. ENSPRYNG summary of product characteristics."},{"issue":"5","key":"10.1016\/j.msard.2022.103772_bib0007","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.103772_bib0008","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/ITT.S287652","article-title":"Drug treatment of neuromyelitis optica spectrum disorders: Out with the old with the new?","volume":"10","author":"Held","year":"2021","journal-title":"ImmunoTargets Ther."},{"issue":"14","key":"10.1016\/j.msard.2022.103772_bib0009","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","article-title":"Satralizumab: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2022.103772_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102542","article-title":"Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience","volume":"46","author":"Huang","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.103772_bib0011","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.msard.2022.103772_bib0012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103772_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000947","article-title":"Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with Aquaporin-4 antibodies","volume":"8","author":"Kim","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2022.103772_bib0014","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103772_bib0015","first-page":"P756","article-title":"Point of no return: Outcomes from acute relapses of neuromyelitis optica depend on severity","author":"Levy","year":"2017","journal-title":"ECTRIMS Online Library (200411)"},{"key":"10.1016\/j.msard.2022.103772_bib0016","unstructured":"Pharmaceuticals and Medical Devices Agency (Japan). New Drugs Approved in FY 2020. Approved in FY 2020. https:\/\/www.pmda.go.jp\/files\/000242574.pdf."},{"key":"10.1016\/j.msard.2022.103772_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103080","article-title":"Asian and African\/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence","volume":"53","author":"Soares-Dos-Reis","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103772_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2022.103772_bib0019","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2022.103772_bib0020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2022.103772_bib0021","unstructured":"U.S. Food & Drug Administration, 2020. ENSPRYNG Prescribing information."},{"issue":"12","key":"10.1016\/j.msard.2022.103772_bib0022","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2022.103772_bib0023","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.103772_bib0024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2022.103772_bib0025","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822002875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822002875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:00:47Z","timestamp":1761901247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822002875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":25,"alternative-id":["S2211034822002875"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103772","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103772"}}